Arca Biopharma Inc. (ABIO) 3.13 $ABIO
Global Mucositis Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Cleveland BioLabs, Acta Dental, ARCA Biopharma - Research and Markets
BusinessWire - Fri Jun 10, 10:47AM CDT
Research and Markets has announced the addition of the "Mucositis Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
ABIO: 3.13 (-0.17), CBLI: 2.61 (+0.01)
ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Wed May 11, 3:30PM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March 31, 2016, and provided a business update.
ABIO: 3.13 (-0.17)
ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial
BusinessWire - Mon Apr 18, 8:00AM CDT
--Outcome of Interim Efficacy Analysis of Data from Approximately 150 Patients Anticipated in the Second Quarter of 2017
ABIO: 3.13 (-0.17)
ARCA biopharma Announces Fiscal Year 2015 Financial Results and Provides Business Update
BusinessWire - Thu Mar 17, 3:30PM CDT
--GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation
ABIO: 3.13 (-0.17)
Applying Lessons from KBIO
ACCESSWIRE - Tue Dec 08, 8:01AM CST
LAS VEGAS, NV / ACCESSWIRE / December 8, 2015 / KaleBios Pharmaceuticals shares have gained 1,279% this month. KaloBios has been surging since Shkreli bought a 70% stake in the company, rescuing it from insolvency. Chief Executive Officer Martin Shkreli has been pushing all the right buttons since taking charge of the company early in November, including Friday's announcement that the company will no longer lend stock to people looking to short sell it.
KBIO: 11.03 (-12.56), ABIO: 3.13 (-0.17)
2 Micro-Cap Opportunities in Atrial Fibrillation
ACCESSWIRE - Mon Nov 30, 8:38AM CST
REDONDO BEACH, CA / ACCESSWIRE / November 30, 2015 / Atrial fibrillation - or A-fib - is the most common cardiac arrhythmia, affecting roughly five million Americans, according to the American Journal of Cardiology. When the heart's upper two chambers - known as the atria - become irregular, blood pools in the chambers and predisposes a person to the formation of clots that may cause a stroke. A-fib is particularly dangerous for patients that have experienced or are experiencing cardiac trauma.
CRME: 4.96 (-0.38), ISIS: 57.56 (-0.28), MDT: 85.70 (-0.08), GILD: 84.45 (-1.32), MRK: 56.81 (-0.37), ABIO: 3.13 (-0.17), LH: 130.30 (-0.89)
Biotechs Under 20 Dollars Poised to Breakout
ACCESSWIRE - Mon Nov 23, 2:08PM CST
LAS VEGAS, NV / ACCESSWIRE / November 23, 2015 / According to Global Analyst Reports, the world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by 2015.
KBIO: 11.03 (-12.56), ABIO: 3.13 (-0.17)
ARCA biopharma to Present at the 27th Annual Piper Jaffray Healthcare Conference
BusinessWire - Thu Nov 19, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it will make a presentation at the 27th Annual Piper Jaffray Healthcare Conference.
ABIO: 3.13 (-0.17)
2 Important Takeaways from ARCA Biopharma's Q3 Results
ACCESSWIRE - Wed Nov 18, 8:42AM CST
REDONDO BEACH, CA / ACCESSWIRE / November 18, 2015 / ARCA biopharma (NASDAQ: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, recently announced its third quarter financial results and provided a business update. While the results were largely in-line with expectations, there were two key takeaways that shareholders and potential investors should note - its $41.5 million cash runway and the successful rollout of its revised trial protocols.
CYTK: 8.21 (-0.09), CRME: 4.96 (-0.38), ABIO: 3.13 (-0.17)
ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update
BusinessWire - Thu Nov 12, 3:30PM CST
--GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation
ABIO: 3.13 (-0.17)
ARCA biopharma CEO Michael Bristow to Present in Two Sessions at the American Heart Association Scientific Sessions 2015
BusinessWire - Thu Nov 05, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its President and CEO, Michael R. Bristow, M.D., Ph.D., will give two invited presentations at the American Heart Association Scientific Sessions 2015 (http://my.americanheart.org/professional/Sessions/ScientificSessions/Scientific-Sessions_UCM_316900_SubHomePage.jsp) being held November 7-11, 2015 in Orlando, Florida.
ABIO: 3.13 (-0.17)
Biotech Pullback: Look to Targeted Therapy Companies
ACCESSWIRE - Mon Oct 19, 8:28AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 19, 2015 / It's with good reason that there is a growing choir of voices heralding the science of targeted therapies as innovative approaches to improving medical care. Advancements in biology and technology underscore discovering specific receptors in cells that can be targeted for meaningful benefits in hard to treat diseases and conditions. There is also a significant diagnostic component in identifying which patients may benefit from certain therapies, while giving direction to avoid other treatments that likely would be ineffective. Combined, these streamline the treatment process and improve outcomes, equating to better quality of life for patients and a quantifiable savings to overburdened healthcare systems.
LOXO: 24.18 (-0.43), MDT: 85.70 (-0.08), FMI: 18.91 (-1.17), GILD: 84.45 (-1.32), LH: 130.30 (-0.89), ABIO: 3.13 (-0.17), SNY: 39.41 (-1.45), CLBS: 0.53 (unch)
ARCA biopharma (ABIO): Leveraging Genetic Targeting to Better Treat Cardiovascular Disease
ACCESSWIRE - Tue Sep 15, 10:20AM CDT
REDONDO BEACH, CA / ACCESSWIRE / September 15, 2015 / Cardiovascular disease is responsible for one-in-four deaths each year in the United States, or roughly 610,000 deaths each year, making it the leading cause of death in both men and women, according to the Centers for Disease Control. Despite causing more deaths than cancer each year, many cardiovascular drugs are based on loose associations rather than the precision genetic targeting that underlies many oncology drugs.
CYTK: 8.21 (-0.09), BSX: 23.02 (-0.30), MDT: 85.70 (-0.08), AZN: 27.97 (-0.99), PFE: 35.29 (-0.02), LH: 130.30 (-0.89), ABIO: 3.13 (-0.17), BMY: 72.65 (-0.08)
Gencaro(TM) Potential Efficacy Preventing Atrial Flutter in Heart Failure Paper to Be Presented at 2015 HFSA Annual Scientific Meeting
BusinessWire - Wed Sep 09, 8:00AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper "Bucindolol Prevents Atrial Flutter via the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism" will be presented at the 19th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) to be held in Washington, D.C. September 26-29, 2015. The paper was recently published in the Journal of Cardiac Failure [http://www.onlinejcf.com/article/S1071-9164(15)00366-8/fulltext], the official journal of the Heart Failure Society of America and the Japanese Heart Failure Society. The lead author on the paper is cardiologist-electrophysiologist Ryan G. Aleong of the University of Colorado, Anschutz Medical Campus, and a co-author on the paper is Dr. Michael R. Bristow, the Company's Chief Executive Officer.
ABIO: 3.13 (-0.17)
ARCA biopharma Announces Second Quarter 2015 Operating Results and Provides Update on Recent Accomplishments
BusinessWire - Tue Aug 11, 3:00PM CDT
--Phase 2B of GENETIC-AF Projected to Complete Enrollment by Year-End 2016
ABIO: 3.13 (-0.17)
Nutritional Supplement Industry Flexes its Muscles as Natural & Pharmaceutical Supplement Products Continue to Hit the Market - Company Prepares for Strong Revenue Growth in 2nd Half of 2015
PR Newswire - Mon Jun 29, 9:27AM CDT
One of the fastest growing industries in the world is the nutritional supplement group, or more broadly known as Vitamins, Minerals and Supplements. It is projected that the industry may top $60 billion in 2021 according to the Nutritional Business Journal. Nutritional Supplement Companies, Retailers and Pharmaceutical Operations in focus today are Axxess Pharma Inc. (OTC: AXXE), Progressive Care Inc. (OTC: RXMD), USANA Health Sciences Inc. (NYSE: USNA), GNC Holdings Inc. (NYSE: GNC) and ARCA biopharma, Inc. (NASDAQ: ABIO)
OPK: 9.30 (-0.31), WWE: 17.59 (-0.32), GNC: 25.65 (-0.52), ABIO: 3.13 (-0.17), USNA: 120.73 (-2.25), RAD: 7.83 (+0.26)
ARCA biopharma raises USD34m in net proceeds from private placement
M2 - Thu Jun 18, 3:05AM CDT
Biopharmaceutical company ARCA biopharma (Nasdaq:ABIO) stated on Wednesday the sale of 42m units in a private placement financing with a select group of institutional investors.
ABIO: 3.13 (-0.17)
ARCA biopharma Announces $37 Million Private Placement
BusinessWire - Thu Jun 11, 7:50AM CDT
--Bucindolol potentially the first genetically-targeted atrial fibrillation prevention treatment
ABIO: 3.13 (-0.17)
BioPharmas are running the FDA Fast Track to Success
M2 - Wed Apr 22, 4:06AM CDT
Biopharma listings tend to reward investors early and often. One of my favorite plays in this sector is the 505(b)(2), an FDA provision that's best known as the fast track announcement. Since these announcements are often made before the street is familiar with the company, or the developmental treatment, the biopharma premium is not priced into the listings. Fast Track designation may be awarded to medicines that are intended to treat a serious or life-threatening disease, or condition, and demonstrate the potential to address unmet medical needs. In addition to reducing the development and approval timeline, the provision can also reduce the financial outlay needed to commercialize the respective products.
HZNP: 17.88 (-0.65), ABIO: 3.13 (-0.17), ORPN: 1.93 (-0.05), DYAX: 38.04 (-0.37)
Global Mucositis Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Cleveland BioLabs, Acta Dental, ARCA Biopharma - Research and Markets
BusinessWire - Fri Jun 10, 10:47AM CDT
Research and Markets has announced the addition of the "Mucositis Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
ABIO: 3.13 (-0.17), CBLI: 2.61 (+0.01)
ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Wed May 11, 3:30PM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March 31, 2016, and provided a business update.
ABIO: 3.13 (-0.17)
ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial
BusinessWire - Mon Apr 18, 8:00AM CDT
--Outcome of Interim Efficacy Analysis of Data from Approximately 150 Patients Anticipated in the Second Quarter of 2017
ABIO: 3.13 (-0.17)
ARCA biopharma Announces Fiscal Year 2015 Financial Results and Provides Business Update
BusinessWire - Thu Mar 17, 3:30PM CDT
--GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation
ABIO: 3.13 (-0.17)
Applying Lessons from KBIO
ACCESSWIRE - Tue Dec 08, 8:01AM CST
LAS VEGAS, NV / ACCESSWIRE / December 8, 2015 / KaleBios Pharmaceuticals shares have gained 1,279% this month. KaloBios has been surging since Shkreli bought a 70% stake in the company, rescuing it from insolvency. Chief Executive Officer Martin Shkreli has been pushing all the right buttons since taking charge of the company early in November, including Friday's announcement that the company will no longer lend stock to people looking to short sell it.
KBIO: 11.03 (-12.56), ABIO: 3.13 (-0.17)
2 Micro-Cap Opportunities in Atrial Fibrillation
ACCESSWIRE - Mon Nov 30, 8:38AM CST
REDONDO BEACH, CA / ACCESSWIRE / November 30, 2015 / Atrial fibrillation - or A-fib - is the most common cardiac arrhythmia, affecting roughly five million Americans, according to the American Journal of Cardiology. When the heart's upper two chambers - known as the atria - become irregular, blood pools in the chambers and predisposes a person to the formation of clots that may cause a stroke. A-fib is particularly dangerous for patients that have experienced or are experiencing cardiac trauma.
CRME: 4.96 (-0.38), ISIS: 57.56 (-0.28), MDT: 85.70 (-0.08), GILD: 84.45 (-1.32), MRK: 56.81 (-0.37), ABIO: 3.13 (-0.17), LH: 130.30 (-0.89)
Biotechs Under 20 Dollars Poised to Breakout
ACCESSWIRE - Mon Nov 23, 2:08PM CST
LAS VEGAS, NV / ACCESSWIRE / November 23, 2015 / According to Global Analyst Reports, the world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by 2015.
KBIO: 11.03 (-12.56), ABIO: 3.13 (-0.17)
ARCA biopharma to Present at the 27th Annual Piper Jaffray Healthcare Conference
BusinessWire - Thu Nov 19, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it will make a presentation at the 27th Annual Piper Jaffray Healthcare Conference.
ABIO: 3.13 (-0.17)
2 Important Takeaways from ARCA Biopharma's Q3 Results
ACCESSWIRE - Wed Nov 18, 8:42AM CST
REDONDO BEACH, CA / ACCESSWIRE / November 18, 2015 / ARCA biopharma (NASDAQ: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, recently announced its third quarter financial results and provided a business update. While the results were largely in-line with expectations, there were two key takeaways that shareholders and potential investors should note - its $41.5 million cash runway and the successful rollout of its revised trial protocols.
CYTK: 8.21 (-0.09), CRME: 4.96 (-0.38), ABIO: 3.13 (-0.17)
ARCA biopharma Announces Third Quarter 2015 Financial Results and Provides Business Update
BusinessWire - Thu Nov 12, 3:30PM CST
--GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation
ABIO: 3.13 (-0.17)
ARCA biopharma CEO Michael Bristow to Present in Two Sessions at the American Heart Association Scientific Sessions 2015
BusinessWire - Thu Nov 05, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its President and CEO, Michael R. Bristow, M.D., Ph.D., will give two invited presentations at the American Heart Association Scientific Sessions 2015 (http://my.americanheart.org/professional/Sessions/ScientificSessions/Scientific-Sessions_UCM_316900_SubHomePage.jsp) being held November 7-11, 2015 in Orlando, Florida.
ABIO: 3.13 (-0.17)
Biotech Pullback: Look to Targeted Therapy Companies
ACCESSWIRE - Mon Oct 19, 8:28AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 19, 2015 / It's with good reason that there is a growing choir of voices heralding the science of targeted therapies as innovative approaches to improving medical care. Advancements in biology and technology underscore discovering specific receptors in cells that can be targeted for meaningful benefits in hard to treat diseases and conditions. There is also a significant diagnostic component in identifying which patients may benefit from certain therapies, while giving direction to avoid other treatments that likely would be ineffective. Combined, these streamline the treatment process and improve outcomes, equating to better quality of life for patients and a quantifiable savings to overburdened healthcare systems.
LOXO: 24.18 (-0.43), MDT: 85.70 (-0.08), FMI: 18.91 (-1.17), GILD: 84.45 (-1.32), LH: 130.30 (-0.89), ABIO: 3.13 (-0.17), SNY: 39.41 (-1.45), CLBS: 0.53 (unch)
ARCA biopharma (ABIO): Leveraging Genetic Targeting to Better Treat Cardiovascular Disease
ACCESSWIRE - Tue Sep 15, 10:20AM CDT
REDONDO BEACH, CA / ACCESSWIRE / September 15, 2015 / Cardiovascular disease is responsible for one-in-four deaths each year in the United States, or roughly 610,000 deaths each year, making it the leading cause of death in both men and women, according to the Centers for Disease Control. Despite causing more deaths than cancer each year, many cardiovascular drugs are based on loose associations rather than the precision genetic targeting that underlies many oncology drugs.
CYTK: 8.21 (-0.09), BSX: 23.02 (-0.30), MDT: 85.70 (-0.08), AZN: 27.97 (-0.99), PFE: 35.29 (-0.02), LH: 130.30 (-0.89), ABIO: 3.13 (-0.17), BMY: 72.65 (-0.08)
Gencaro(TM) Potential Efficacy Preventing Atrial Flutter in Heart Failure Paper to Be Presented at 2015 HFSA Annual Scientific Meeting
BusinessWire - Wed Sep 09, 8:00AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper "Bucindolol Prevents Atrial Flutter via the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism" will be presented at the 19th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) to be held in Washington, D.C. September 26-29, 2015. The paper was recently published in the Journal of Cardiac Failure [http://www.onlinejcf.com/article/S1071-9164(15)00366-8/fulltext], the official journal of the Heart Failure Society of America and the Japanese Heart Failure Society. The lead author on the paper is cardiologist-electrophysiologist Ryan G. Aleong of the University of Colorado, Anschutz Medical Campus, and a co-author on the paper is Dr. Michael R. Bristow, the Company's Chief Executive Officer.
ABIO: 3.13 (-0.17)
ARCA biopharma Announces Second Quarter 2015 Operating Results and Provides Update on Recent Accomplishments
BusinessWire - Tue Aug 11, 3:00PM CDT
--Phase 2B of GENETIC-AF Projected to Complete Enrollment by Year-End 2016
ABIO: 3.13 (-0.17)
Nutritional Supplement Industry Flexes its Muscles as Natural & Pharmaceutical Supplement Products Continue to Hit the Market - Company Prepares for Strong Revenue Growth in 2nd Half of 2015
PR Newswire - Mon Jun 29, 9:27AM CDT
One of the fastest growing industries in the world is the nutritional supplement group, or more broadly known as Vitamins, Minerals and Supplements. It is projected that the industry may top $60 billion in 2021 according to the Nutritional Business Journal. Nutritional Supplement Companies, Retailers and Pharmaceutical Operations in focus today are Axxess Pharma Inc. (OTC: AXXE), Progressive Care Inc. (OTC: RXMD), USANA Health Sciences Inc. (NYSE: USNA), GNC Holdings Inc. (NYSE: GNC) and ARCA biopharma, Inc. (NASDAQ: ABIO)
OPK: 9.30 (-0.31), WWE: 17.59 (-0.32), GNC: 25.65 (-0.52), ABIO: 3.13 (-0.17), USNA: 120.73 (-2.25), RAD: 7.83 (+0.26)
ARCA biopharma raises USD34m in net proceeds from private placement
M2 - Thu Jun 18, 3:05AM CDT
Biopharmaceutical company ARCA biopharma (Nasdaq:ABIO) stated on Wednesday the sale of 42m units in a private placement financing with a select group of institutional investors.
ABIO: 3.13 (-0.17)
ARCA biopharma Announces $37 Million Private Placement
BusinessWire - Thu Jun 11, 7:50AM CDT
--Bucindolol potentially the first genetically-targeted atrial fibrillation prevention treatment
ABIO: 3.13 (-0.17)
BioPharmas are running the FDA Fast Track to Success
M2 - Wed Apr 22, 4:06AM CDT
Biopharma listings tend to reward investors early and often. One of my favorite plays in this sector is the 505(b)(2), an FDA provision that's best known as the fast track announcement. Since these announcements are often made before the street is familiar with the company, or the developmental treatment, the biopharma premium is not priced into the listings. Fast Track designation may be awarded to medicines that are intended to treat a serious or life-threatening disease, or condition, and demonstrate the potential to address unmet medical needs. In addition to reducing the development and approval timeline, the provision can also reduce the financial outlay needed to commercialize the respective products.
HZNP: 17.88 (-0.65), ABIO: 3.13 (-0.17), ORPN: 1.93 (-0.05), DYAX: 38.04 (-0.37)
